Tokushima University / Educator and Researcher Directory --- Fujihara, Toshitaka

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Yoshimi Bando and Yasushi Takagi : Metastatic tumor to the orbital cavity from a primary carcinoma of the uterine cervix : a case report., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 355-357, 2019. (Summary) Metastatic tumors to the orbit of the eye, especially from primary carcinomas of the uterine cervix are very rare. A 64-year-old woman with a history of carcinoma of the uterine cervix presented with right eye pain and blepharoptosis for 2 weeks. Magnetic resonance imaging revealed a mass at the right orbital apex. Surgical extirpation was performed due to severe pain. Postoperative pathology demonstrated a poorly differentiated squamous cell carcinoma. The origin was ultimately considered to be the carcinoma of the uterine cervix. In conclusion, this report describes a rare case of a metastatic tumor at the orbital apex derived from the cervix of the uterus. J. Med. Invest. 66 : 355-357, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114169 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.355 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656305 ● Search Scopus @ Elsevier (PMID): 31656305 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.355 (Tokushima University Institutional Repository: 114169, DOI: 10.2152/jmi.66.355, PubMed: 31656305)
2.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Kazuhito Matsuzaki, Hideo Mure, Shinji Nagahiro and Yasushi Takagi : The risk of hemorrhage in stereotactic biopsy for brain tumors., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 314-318, 2019. (Summary) Objective : One major complication associated with STB is intratumoral hematoma, which is also the most common cause of morbidity related to permanent paralysis and mortality in STB. The risk of perioperative hemorrhage is generally between 1% and 10%, but this could be an underestimation since it is not common for many neurosurgeons to perform CT scans after uncomplicated STBs. In this study, we describe the incidence of cerebral hemorrhage, including asymptomatic cerebral hemorrhage. Methods : We recently reviewed data on the diagnosis rate and occurrence of complications, including symptomatic and asymptomatic cerebral hemorrhage, in 80 patients who underwent STB at our facility between 2005 and 2014. Results : Histological diagnosis was established for 75 cases (93.8%), glioma was the most frequently encountered tumor. Symptomatic hemorrhage was observed in two cases (2.6%), with the symptoms subsiding within two days. The morbidity and mortality rate was 0%. However, asymptomatic hemorrhages were observed in 23 cases (28.8%). Conclusion : Stereotactic biopsy is a less invasive procedure for obtaining samples of brain tumors for diagnosis. The bleeding of the tissue-resection cavity that includes asymptomatic hemorrhage occurs at a constant rate. It is important to reduce the symptomatic bleeding associated with stereotactic biopsy. J. Med. Invest. 66 : 314-318, August, 2019. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Biopsy / Brain / Brain Neoplasms / Cerebral Hemorrhage / Female / Humans / Male / Middle Aged / Stereotaxic Techniques / Young Adult (Tokushima University Institutional Repository) ● Metadata: 114088 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.314 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656296 ● Search Scopus @ Elsevier (PMID): 31656296 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.314 (Tokushima University Institutional Repository: 114088, DOI: 10.2152/jmi.66.314, PubMed: 31656296)
3.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Kazuhito Matsuzaki, KT Kitazato, Ryotaro Otsuka, Keijiro Hara, Hideo Mure, Toshiyuki Okazaki, Kazuyuki Kuwayama, Shinji Nagahiro and Yasushi Takagi : Down-regulation of MDR1 by Ad-DKK3 via Akt/NFB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model, Journal of Neuro-Oncology, Vol.139, No.2, 323-332, 2018. (Summary) Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1. GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination. Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway. Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells. (Tokushima University Institutional Repository) ● Metadata: 112895 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-018-2894-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29779087 ● Summary page in Scopus @ Elsevier: 2-s2.0-85047143200 (Tokushima University Institutional Repository: 112895, DOI: 10.1007/s11060-018-2894-5, PubMed: 29779087, Elsevier: Scopus)
4.	Aya Sato, Yoshifumi Mizobuchi, Kohhei Nakajima, Kenji Shono, Toshitaka Fujihara, Teruyoshi Kageji, Keiko Kitazato, Kazuhito Matsuzaki, Hideo Mure, Kazuyuki Kuwayama, Akiko Sumi, Hideyuki Saya, Oltea Sampetrean and Shinji Nagahiro : Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma., Journal of Neuro-Oncology, Vol.132, No.2, 231-238, 2017. (Summary) Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial. (Keyword) Animals / Apoptosis / Brain / Brain Neoplasms / Celecoxib / Cell Line, Tumor / Cell Proliferation / Cyclooxygenase 2 / Cyclooxygenase 2 Inhibitors / Enzyme Inhibitors / Female / Gene Expression Regulation, Neoplastic / Glioma / Humans / Inhibitor of Apoptosis Proteins / Inhibitor of Differentiation Proteins / Male / Mice / Mice, Inbred C57BL / Mice, Transgenic / Neoplasm Proteins / Proto-Oncogene Proteins c-akt / Signal Transduction (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-017-2380-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28283800 ● Search Scopus @ Elsevier (PMID): 28283800 ● Search Scopus @ Elsevier (DOI): 10.1007/s11060-017-2380-5 (DOI: 10.1007/s11060-017-2380-5, PubMed: 28283800)

Proceeding of International Conference:

1.	Kenji Shono, Izumi Yamaguchi, Toshitaka Fujihara, Keiko Kitazato, Kohhei Nakajima, Yoshifumi Mizobuchi, Hideo Mure, Kohhei Nakajima, Junichiro Satomi, Shinji Nagahiro and Yasushi Takagi : Celecoxib inhibits proliferation and induces apoptosis in glioma stem cells and an animal model of glioblastoma., 22ND ANNUAL SCIENTIFIC MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY, San Francisco, Nov. 2017.
2.	Junichiro Satomi, Yasuhisa Kanematsu, Masaaki Korai, Yuki Yamamoto, Nobuaki Yamamoto, Yoshifumi Mizobuchi, Hideo Mure, Yoshiteru Tada, Kohhei Nakajima, Toshiyuki Okazaki and Toshitaka Fujihara : Acute stroke management using image sharing on smart phones and tablet devices, 14TH CONGRESS OF THE WORLD FEDERATION OF INTERVENTIONAL AND THERAPEUTIC NEURORADIOLOGY, Budapest, Oct. 2017.

Proceeding of Domestic Conference:

1.	Toshitaka Fujihara, Yoshiteru Tada, Kenji Shimada, Yasuhisa Kanematsu and Yasushi Takagi : 内頚動脈海綿静脈洞瘻に急性症候発作重積を合併した1例, 第14回日本てんかん学会中国・四国地方会, Feb. 2020.
2.	Toshitaka Fujihara, Yoshiteru Tada, Mai Azumi and Yasushi Takagi : 海馬からのてんかん性放電が乏しかった海馬硬化症の1例, 第7回全国てんかんセンター協議会広島大会, Feb. 2020.
3.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, 森達夫, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の活動状況, 第7回全国てんかんセンター協議会広島大会, Feb. 2020.
4.	Yoshiteru Tada, Toshitaka Fujihara, 香川幸太, 片桐匡弥, 瀬山剛, 飯田幸治 and Yasushi Takagi : 遠隔てんかん症例検討会による薬剤抵抗性側頭葉てんかん治療方針の決定について, 第43回日本てんかん外科学会, Jan. 2020.
5.	Toshitaka Fujihara, Yoshiteru Tada, Yasuhisa Kanematsu and Yasushi Takagi : Wadatestにて言語優位半球を同定できなかった薬剤抵抗性側頭葉てんかんの一例, 第43回日本てんかん外科学会, Jan. 2020.
6.	Masahito Nakataki, Hiroaki Edo, Yoshiteru Tada, Yoshihiro Touda, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, Kenji Mori and Tetsuro Ohmori : てんかん発作や精神症状と関連しない生活の質, 第53回日本てんかん学会学術集会, Nov. 2019.
7.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 脳腫瘍手術における周術期抗てんかん薬使用と術後発作抑制効果についての検討, 第53回日本てんかん学会学術集会, Oct. 2019.
8.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の紹介, 第53回日本てんかん学会学術集会, Oct. 2019.
9.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 眼窩内に転移した子宮頚癌の1例, 日本脳神経外科学会第78回学術集会, Oct. 2019.
10.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における転移性脳腫瘍に対する術後放射線療法の検討, 日本脳神経外科学会第78回学術集会, Oct. 2019.
11.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 高齢発症てんかんの臨床的特徴, 日本脳神経外科学会第78回学術集会, Oct. 2019.
12.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi, Yoshiteru Tada and Yasushi Takagi : Perioperative prophylactic antiepileptic drug use and postoperative seizure in brain tumor surgery, Neurologia Medico-Chirurgica, Oct. 2019.
13.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 中枢神経原発性悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 第36回日本脳腫瘍学会学術集会, Dec. 2018.
14.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 穿刺様頭痛で発見された中枢神経アスペルギルス症の1例, 第46回日本頭痛学会総会, Nov. 2018.
15.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Kenji Mori and Yasushi Takagi : 高齢発症てんかんの臨床的特徴，新規抗てんかん薬の効果, 日本脳神経外科学会第77回学術総会, Oct. 2018.
16.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshiyuki Okazaki, Hideo Mure and Yasushi Takagi : 膠芽腫におけるDKK3遺伝子導入による薬剤排泄ポンプの発現抑制の意義, 日本脳神経外科学会第77回学術総会, Oct. 2018.
17.	鹿草宏, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 慢性硬膜下血腫の手術方法の検討, 日本脳神経外科学会第77回学術総会, Oct. 2018.
18.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における中枢神経原発悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 日本脳神経外科学会第77回学術総会, Oct. 2018.
19.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Shinji Nagahiro and Yasushi Takagi : 顔面痙攣に対する手術手技 "shelter method" の有効性と長期予後, 日本脳神経外科学会第77回学術総会, Oct. 2018.
20.	Shoichi Hatada, 小山広士, Toshitaka Fujihara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : 短期間で出血を繰り返した多発脳病変の1例, 第32回中国四国脳腫瘍研究会, Sep. 2018.
21.	Yoshiteru Tada, Toshitaka Fujihara, Aya Gohji, Tatsuo Mori, Yoshihiro Touda, Kenji Mori, 飯田幸治, Junichiro Satomi and Yasushi Takagi : 術前精査中にバルブロ酸の追加が著効したrolandic crtical dysplasiaに1例, 第41回日本てんかん外科学会, Jan. 2018.
22.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 非痙攣性てんかん重積診断におけるArterial Spin Labeling法の有用性, 第51回日本てんかん学会年次学術集会, Nov. 2017.
23.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure and Shinji Nagahiro : 同側の未破裂中大脳動脈瘤を合併した左海馬硬化症による難治性内側側頭葉てんかんの一例, 第11回てんかん学会中国・四国地方会, Oct. 2017.
24.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 当院で経験した非痙攣性てんかん重積症例の検討, 日本脳神経外科学会第76回学術総会, Oct. 2017.

Et cetera, Workshop:

1.	Tatsuya Haboshi, Yoshiteru Tada, Toshitaka Fujihara, 亘雄也, Kohhei Nakajima and Yasushi Takagi : 前方脳梁離断術を施行した成人難治性てんかんの2例, 第43回徳島脳神経外科談話会, Dec. 2017.
2.	Toshitaka Fujihara, Yoshiteru Tada and Shinji Nagahiro : 当院で経験した非痙攣性てんかん重積症例の検討, 第4回徳島脳神経疾患談話会, Mar. 2017.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Search by Researcher Number (90551060)

Fujihara, Toshitaka

Research Activity

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)